衣折麦布/瑞舒伐他汀联用与双倍剂量瑞舒伐他汀治疗冠心病血脂异常患者的临床效果观察  

Observation on clinical treatment outcome of dyslipidemia in coronary artery disease by ezetimible/rosuvastatin and double-dosage rosuvastatin

作　　者：季顺民[1] 陈瑜[1] 钱勇[1] 丁卫东[1] 王俊[2] 

机构地区：[1]江苏省海安县肿瘤医院内科,海安226681 [2]南京军区南京总医院

出　　处：《南通大学学报（医学版）》2014年第5期384-386,共3页Journal of Nantong University(Medical sciences)

摘　　要：目的:比较衣折麦布/瑞舒伐他汀与双倍剂量瑞舒伐他汀对冠心病血脂异常患者的疗效。方法:以2012年6月—2013年12月在我院接受治疗的110例冠心病血脂异常患者为研究对象,按照治疗方式的不同,随机分为两组,即衣折麦布/瑞舒伐他汀(10 mg/d+10 mg/d)联合治疗组(E/R组)与双倍剂量瑞舒伐他汀(20 mg/d)治疗组(D/R组),每组各55例比较两组患者服药12周的治疗效果。结果:与治疗前相比,E/R组患者总胆固醇(total cholesterol,TC)、三酰甘油及低密度脂蛋白胆固醇水平均显著降低(P<0.05),并且显著低于D/R组患者(P<0.05),而高密度脂蛋白胆固醇水平显著升高(P<0.05)。与治疗前相比,虽然E/R组7-烯胆烷醇/TC校正值显著升高(P<0.05),但是菜油固醇/TC的校正值显著降低(P<0.05),且后者的降低幅度1.35±0.70远大于前者0.41±0.21。同时,虽然D/R组7-烯胆烷醇/TC校正值显著降低(P<0.05),但是菜油固醇/TC的校正值显著升高(P<0.05),且前者的降低幅度0.08±0.01远小于后者的升高幅度0.34±0.15。结论:与双倍剂量瑞舒伐他汀治疗相比,衣折麦布/瑞舒伐他汀联用调脂作用更佳、更稳定,且胆固醇吸收与合成标志物的测定比血浆胆固醇水平更能反映机体胆固醇的代谢状态。Objective： To compare the curative effect on dislipidemia in coronary artery disease（CAD） patient with ezetimibe/rosuvastatin combination and double dosage rosuvastatin. Methods： From June 2012 to December 2013, 110 consecutive CAD patients with hyperlipidemia were enrolled in our hospital and were assigned into D/R Group and E/R Group, 55 cases each group. Two groups underwent the regimen of double-dosage rosuvastatin（20 mg/d） and ezetimibe（10 mg/d）＋rosuvastatin（10mg/d）, respectively. After 12-week treatment, the curative effect was compared between them. Result： The serum level of triacylyceride（TG）, total cholesterol（TC）, low density lipoprotein cholesterol（LDL-C） were lower than those of prior to treatment in E/R group（P〈0.05）, which were lower than those in D/R group（P〈0.05）, whereas the level of high density lipoprotein cholesterol（HDL-C） increased significantly（P〈0.05）. Compared with the pre-treatment, the adjusted ratio of lathosterol/TC in E/R group remarkably increased（P〈0.05）, instead that of Brassicasterol/TC decreased（P〈0.05） by greater extent than the former＇s（1.35±0.70 vs 0.41±0.21）. In addition, through the adjusted ratio of lathosterol/TC in D/R group increased distinctly（P〈0.05）, that of Brassicasterol/TC increased（P〈0.05） by greater extent than the former＇s（0.08±0.01 vs 0.34±0.15）. Conclusion：In contrast to the double-dosage rosuvastatin therapy, the ezetimible/rosuvastatin therapy possesses the better and more stable potency of regulating dyslipidemia. To reflect the metabolism of cholesterol, the determination of cholesterol absorption and synthesis is more suitable than the serum level of cholesterol.

关 键 词：冠状动脉粥样硬化性心脏病 衣折麦布 瑞舒伐他汀 血脂异常 

分 类 号：R541.4[医药卫生—心血管疾病]